Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (DE:BM8)
FRANKFURT:BM8
RESEARCH TOOLSreports
BM8 Analyst Ratings
Strong Buy
19 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BM8 Stock 12 Month Forecast
Average Price Target
€91.07
▲(39.81% Upside)
| Highest Price Target€116.37 | Average Price Target€91.07 | Lowest Price Target€64.14 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
Reiterated
03/27/25
Citi
Reiterated
03/20/25
Piper Sandler
Reiterated
03/17/25
J.P. Morgan
Reiterated
03/14/25
BMO Capital
Reiterated
03/09/25
Leerink Partners
Reiterated
03/06/25
Oppenheimer
Upgraded
02/24/25
Stifel Nicolaus
Reiterated
02/23/25
Truist Financial
Reiterated
02/20/25
Wells Fargo
Reiterated
02/20/25
Barclays
€79.39
Buy
21.87%
Upside
Reiterated
02/20/25
BioMarin Pharmaceutical (BMRN) Gets a Buy from Barclays
Cantor Fitzgerald
€83.08
Buy
27.54%
Upside
Reiterated
02/20/25
Cantor Fitzgerald reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $90.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).
William Blair
―
Hold
―
Reiterated
02/20/25
William Blair Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)
Bernstein
€83.08→€86.77
Buy
33.21%
Upside
Reiterated
02/20/25
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $94 at Bernstein SocGen GroupBernstein SocGen Group analyst William Pickering raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $94.00 (from $90.00) while maintaining a Outperform rating.
Scotiabank
€73.85
Hold
13.37%
Upside
Reiterated
02/20/25
Scotiabank Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
Reiterated
03/27/25
Citi
Reiterated
03/20/25
Piper Sandler
Reiterated
03/17/25
J.P. Morgan
Reiterated
03/14/25
BMO Capital
Reiterated
03/09/25
Leerink Partners
Reiterated
03/06/25
Oppenheimer
Upgraded
02/24/25
Stifel Nicolaus
Reiterated
02/23/25
Truist Financial
Reiterated
02/20/25
Wells Fargo
Reiterated
02/20/25
Barclays
€79.39
Buy
21.87%
Upside
Reiterated
02/20/25
BioMarin Pharmaceutical (BMRN) Gets a Buy from Barclays
Cantor Fitzgerald
€83.08
Buy
27.54%
Upside
Reiterated
02/20/25
Cantor Fitzgerald reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $90.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).
William Blair
―
Hold
―
Reiterated
02/20/25
William Blair Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)
Bernstein
€83.08→€86.77
Buy
33.21%
Upside
Reiterated
02/20/25
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $94 at Bernstein SocGen GroupBernstein SocGen Group analyst William Pickering raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $94.00 (from $90.00) while maintaining a Outperform rating.
Scotiabank
€73.85
Hold
13.37%
Upside
Reiterated
02/20/25
Scotiabank Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)
BM8 Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
17
12
7
14
17
Buy
29
11
8
14
14
Hold
19
9
3
7
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
65
32
18
35
39
Each month's total comprises the sum of three months' worth of ratings.
BM8 Financial Forecast
BM8 Stock Forecast FAQ
What is DE:BM8’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is €91.07.
What is DE:BM8’s upside potential, based on the analysts’ average price target?
BioMarin Pharmaceutical has 39.81% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BioMarin Pharmaceutical a Buy, Sell or Hold?
BioMarin Pharmaceutical has a consensus rating of Strong Buy, which is based on 19 buy ratings, 5 hold ratings and 0 sell ratings.
What is BioMarin Pharmaceutical’s share price target?
The average share price target for BioMarin Pharmaceutical is €91.07. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €116.37 ,and the lowest forecast is €64.14. The average share price target represents 39.81% Increase from the current price of €65.14.
The highest analyst share price target is €116.37 ,and the lowest forecast is €64.14. The average share price target represents 39.81% Increase from the current price of €65.14.
What do analysts say about BioMarin Pharmaceutical?
BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.
How can I buy shares of BioMarin Pharmaceutical?
To buy shares of DE:BM8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.